Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the ...
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient ...
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for ...
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma ...
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx Pharmaceutical entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. Ultragenyx received the voucher upon FDAs ...
Pharmaceutical Executive spoke with Mark Talens, CCO of PAXAFE at LogiPharma 2026 in Boston. During the conversation., the executive discussed a variety of issues and updates on m ...
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability ...
Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring ...
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality ...
At ESC Congress 2026, incretin-based therapies, including GLP-1 receptor agonists, featured across heart failure (HF), chronic kidney disease (CKD), atrial fibrillation (AF), obesity and ...
Sponsors in North America and APAC with plans to enter the European marketplace must contend with Joint Clinical Assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results